Palisade Bio Receives Bullish Analyst Rating as Lead IBD Drug Advances Toward Phase 2 Trials
Oppenheimer has initiated coverage of Palisade Bio Inc., assigning a Buy rating and an $8 price target. The firm views the company's lead drug candidate, PALI-2108—a once-daily oral PDE4 inhibitor prodrug—as having strong potential in the inflammatory bowel disease (IBD) market due to its targeted activation mechanism and favorable early trial results. PALI-2108 has demonstrated positive outcomes across Phase 1a and 1b trials, including for ulcerative colitis and fibrostenotic Crohn's disease. The FDA recently cleared the Investigational New Drug (IND) application, enabling Palisade Bio to begin its global Phase 2 ASCENTRA-UC trial in patients with moderately to severely active ulcerative colitis by late 2026. Analyst Leland Gershell highlighted that PALI-2108 could fill a critical gap between biologics and oral maintenance therapies. Oppenheimer forecasts peak U.S. sales of $2.6 billion for UC in 2040 and $2.8 billion for fibrostenotic CD by 2041, positioning the drug as a next-generation PDE4 inhibitor with improved tolerability over existing options.
Topics: drug development FDA clearance inflammatory bowel disease (IBD) Phase 2 clinical trial